The company’s leadership team, including CEO Erik Lundgren and Chief Medical Officer Michael A. Panzara, will be joined by neurologists Amit Bar-Or of the University of Pennsylvania and Stephen Krieger of Mount Sinai. The panel will evaluate the clinical trajectory of vidofludimus calcium, an investigational molecule that utilizes Nurr1 activation and DHODH inhibition to target both inflammatory and neurodegenerative aspects of multiple sclerosis.
Immunic Sets R&D Day Ahead of Phase 3 MS Trial Results
With top-line data from its Phase 3 ENSURE trials in relapsing multiple sclerosis expected by the end of 2026, Immunic, Inc. will host a virtual R&D day on September 9. The event aims to detail the potential of its lead oral therapy, vidofludimus calcium, in addressing neurodegenerative drivers of the disease.
Beyond technical data, the presenters plan to analyze current treatment paradigms and the evolving needs of the patient population. The webinar is scheduled for September 9, 2026, from 11:00 am to 12:30 pm ET, providing a platform for stakeholders to examine how this dual-action therapy may differentiate itself from traditional anti-inflammatory approaches. Prospective attendees can register for the virtual session via the company’s investor relations portal.
Comments (0)
No comments yet. Be the first!